Literature DB >> 7472281

17 Alpha-ethinyl estradiol is more potent than estradiol in receptor interactions with isolated hepatic parenchymal cells.

R B Dickson, A J Eisenfeld.   

Abstract

Estradiol (E2) and 17 alpha-ethinyl estradiol (EE2) were compared for their abilities to promote nuclear translocation of the hepatic estrogen receptor. High levels of nonradioactive E2 and EE2 were incubated in vitro with isolated rat liver parenchymal cells. Cytosol and nuclear receptors were then partially purified and measured by exchange with [3H]E2. E2 was required in an approximately 100-fold higher concentration than EE2 for promotion of receptor translocation (for example, 10(-5) M E2 was equivalent to 10(-7) M EE2). When the metabolisms of the estrogens by parenchymal cells were compared, it was found that [3H]E2 was metabolized much more extensively than [3H]EE2 after a short time interval. Inhibitors of estrogen metabolism were used to test the hypothesis that the high dose requirement for receptor translocation may be due to metabolism. In isolated liver cells, SKF 525A (beta-diethylaminoethyl-2,2-diphenylpentanoate; an inhibitor of hepatic mixed function oxidase) could increase levels of unmetabolized EE2, cytosol receptor deletion, and nuclear receptor accumulation. SKF 525A alone was not sufficient to increase levels of unmetabolized E2 or receptor translocation in the presence of this estrogen. When testosterone (a transient inhibitor of the 17-oxidoreductase active on E2) was included in cellular incubations (using female liver cells) with E2 and SKF 525A, levels of unmetabolized E2 were substantially increased in conjunction with increased depletion of cytosol receptors and increased levels of nuclear receptors. These data suggest that hepatic metabolism may limit the availability of estrogens for binding to receptors. The present study suggests that E2 is more extensively metabolized than EE2 to metabolites which are less capable of promotion of receptor translocation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7472281     DOI: 10.1210/endo-108-4-1511

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Improving Estrogenic Compound Screening Efficiency by Using Self-Modulating, Continuously Bioluminescent Human Cell Bioreporters Expressing a Synthetic Luciferase.

Authors:  Tingting Xu; Andrew Kirkpatrick; Jody Toperzer; Steven Ripp; Dan Close
Journal:  Toxicol Sci       Date:  2019-04-01       Impact factor: 4.849

2.  17β-Estradiol and 17α-Ethinyl Estradiol Exhibit Immunologic and Epigenetic Regulatory Effects in NZB/WF1 Female Mice.

Authors:  Rujuan Dai; Michael R Edwards; Bettina Heid; S Ansar Ahmed
Journal:  Endocrinology       Date:  2019-01-01       Impact factor: 4.736

3.  Combined Oral Contraceptives Increase High-Sensitivity C-Reactive Protein but Not Haptoglobin in Female Athletes.

Authors:  Sabina Cauci; Maria Pia Francescato; Francesco Curcio
Journal:  Sports Med       Date:  2017-01       Impact factor: 11.136

Review 4.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

5.  Understanding the cognitive impact of the contraceptive estrogen Ethinyl Estradiol: tonic and cyclic administration impairs memory, and performance correlates with basal forebrain cholinergic system integrity.

Authors:  Sarah E Mennenga; Julia E Gerson; Stephanie V Koebele; Melissa L Kingston; Candy W S Tsang; Elizabeth B Engler-Chiurazzi; Leslie C Baxter; Heather A Bimonte-Nelson
Journal:  Psychoneuroendocrinology       Date:  2015-01-12       Impact factor: 4.905

6.  Natural and synthetic estrogens specifically alter nicotine demand and cue-induced nicotine seeking in female rats.

Authors:  Erin E Maher; Paula F Overby; Amanda H Bull; Joshua S Beckmann; Jonna M Leyrer-Jackson; Stephanie V Koebele; Heather A Bimonte-Nelson; Cassandra D Gipson
Journal:  Neuropharmacology       Date:  2021-08-17       Impact factor: 5.273

7.  Exploration of functional health, mental well-being and cross-sex hormone use in a sample of Thai male-to-female transgendered persons (kathoeys).

Authors:  Louis J Gooren; Tanapong Sungkaew; Erik J Giltay
Journal:  Asian J Androl       Date:  2013-01-28       Impact factor: 3.285

8.  Idoxifene and estradiol enhance antiapoptotic activity through estrogen receptor-beta in cultured rat hepatocytes.

Authors:  Hiroshi Inoue; Ichiro Shimizu; Guangming Lu; Mina Itonaga; Xuezhi Cui; Yoshihito Okamura; Masayuki Shono; Hirohito Honda; Satoshi Inoue; Masami Muramatsu; Susumu Ito
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

9.  Are in vitro methods for the detection of endocrine potentials in the aquatic environment predictive for in vivo effects? Outcomes of the Projects SchussenAktiv and SchussenAktivplus in the Lake Constance Area, Germany.

Authors:  Anja Henneberg; Katrin Bender; Ludek Blaha; Sabrina Giebner; Bertram Kuch; Heinz-R Köhler; Diana Maier; Jörg Oehlmann; Doreen Richter; Marco Scheurer; Ulrike Schulte-Oehlmann; Agnes Sieratowicz; Simone Ziebart; Rita Triebskorn
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

10.  Editor's Highlight: Development of an In vitro Assay Measuring Uterine-Specific Estrogenic Responses for Use in Chemical Safety Assessment.

Authors:  Michelle M Miller; Rebecca A Alyea; Caroline LeSommer; Daniel L Doheny; Sean M Rowley; Kristin M Childs; Pergentino Balbuena; Susan M Ross; Jian Dong; Bin Sun; Melvin A Andersen; Rebecca A Clewell
Journal:  Toxicol Sci       Date:  2016-08-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.